Mean corpuscular volume in *HFE* p.C282Y/p.H63D compound heterozygotes with high iron

phenotypes: clinical and laboratory associations

Running title: MCV in *HFE* p.C282Y/p.H63D compound heterozygotes

James C. Barton[1,2], J. Clayborn Barton[2], and Ronald T. Acton[2,3]

[1] Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA

[2] Southern Iron Disorders Center, Birmingham, Alabama, USA

[3] Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama,

USA

James C. Barton (corresponding author): bartonjames336@gmail.com; ORCID 0000-0003-2876-

8276

J. Clayborn Barton: jbarton205@gmail.com; ORCID 0000-0002-2646-4466

Ronald T. Acton: rtakma@bellsouth.net; ORCID 0000-0002-8586-6887

Abstract

Background: Variables that influence mean corpuscular volume (MCV) in *HFE* p.C282Y

(rs1800562)/p.H63D (rs1799945) compound heterozygotes are inadequately defined.

Methods: We retrospectively studied self-reported non-Hispanic white adult compound

heterozygotes with transferrin saturation (TS) >50% and serum ferritin (SF) >300 µg/L (men) or

TS >45% and SF >200 µg/L (women) who participated in primary care-based screening. In post-

screening evaluations, we excluded participants with anemia, pregnancy, or medication use that

increases MCV. We defined heavy alcohol intake as >28 g/d men and >14 g/d women. We

determined associations of MCV with 11 clinical and laboratory variables.

Results: There were 74 participants (37 men, 37 women) of mean age 59±12 (SD) y. Mean

screening TS and SF were 65±13% and 529±169 µg/L (men) and 59±14% and 376±195 µg/L

(women). Post-screening values did not differ significantly. Mean MCV was 95.7±4.0 fL. There

was a negative correlation of MCV with body mass index (p=0.0488) and positive correlations of

MCV with age (p=0.0098), daily heme iron intake (p=0.0333), and daily alcohol intake

(p=0.0113). Mean MCVs of 19 participants with and 55 without heavy alcohol intake were

97.8±3.8 g/d and 95.0±3.9 g/d, respectively; p=0.0074). Linear regression on MCV confirmed

positive associations with age (p=0.0064) and daily alcohol intake (p=0.0151). MCV was not

significantly associated with sex, diabetes, daily intakes of non-heme and supplemental iron,

swollen or tender 2nd/3rd metacarpophalangeal joints, TS, or SF.

Conclusion: MCV in *HFE* p.C282Y/p.H63D compound heterozygotes with high iron phenotypes

is positively associated with age and daily alcohol intake, after adjustment for other variables.

Introduction

HFE, the homeostatic iron regulator (chromosome 6p22.2),[1][2] encodes the cell surface glycoprotein

HFE, an upstream regulator of the hepatic hormone hepcidin (*HAMP,* chromosome 19q13.12), the

central controller of iron homeostasis.[3] In persons of European descent, the most common *HFE*

missense mutations are p.C282Y (rs1800562) and p.H63D (rs1799945).[4] The estimated prevalence

of p.C282Y/p.H63D compound heterozygotes in non-Hispanic white adults in North America is 1

in 49.[5] In persons of European descent in the United Kingdom, the estimated prevalence of

p.C282Y/p.H63D compound heterozygotes is 1 in 31.[4]

Mean corpuscular volume (MCV) is the average size of red blood cells.[6] In Western Australia,

mean MCVs of *HFE* p.C282Y/p.H63D compound heterozygotes were significantly higher than

those of subjects without either p.C282Y or p.H63D (*HFE* wt/wt) but were not abnormally

elevated.[7][8] In contrast, the mean MCVs of referred p.C282Y/p.H63D compound heterozygotes in

Alabama[9] and the Netherlands[10] and corresponding wt/wt control subjects did not differ

significantly. In genome-wide association studies of adults of European descent, there were

positive statistical associations between MCV and p.C282Y[11][12][13] and p.H63D,[11] although HFE

protein is not expressed in erythroid colonies.[14] We found no comprehensive study of the

relationships between MCV and clinical and laboratory variables in adults with p.C282Y/p.H63D

compound heterozygosity.

We performed a retrospective study of 74 adult self-reported non-Hispanic white *HFE*

p.C282Y/p.H63D compound heterozygotes who 1) had both elevated TS and elevated SF in a

population screening program[15] and 2) did not have anemia, report pregnancy, or use medications

that increase MCV. The aim of this study was to define the relationships between MCV and the

following clinical and laboratory variables: age, sex, BMI, diabetes, daily intakes of heme, non-

heme, and supplemental iron, daily intakes of alcohol, swollen or tender 2nd/3rd

metacarpophalangeal (MCP) joints, TS, and SF. We compare the present observations with those

of previously reported hemochromatosis and population cohorts and propose the relevance of the

present results.

Methods

Ethics approval statement

The Hemochromatosis and Iron Overload Screening (HEIRS) Study, conducted by the National

Heart, Lung, and Blood Institute and the National Human Genome Research Institute, in

accordance with the principles of the Declaration of Helsinki, evaluated diverse aspects of

hemochromatosis, iron overload, and iron-related disorders in a primary care-based sample of

101,168 adults enrolled during the interval 2001-2002 at four Field Centers in the U.S. and one in

Canada.[5 15 16]

Local Institutional Review Boards of the HEIRS Study Coordinating Center (Wake Forest

University Institutional Review Board, Wake Forest University), the HEIRS Study Central

Laboratory (University of Minnesota Institutional Review Board, University of Minnesota), and

the HEIRS Study Field Centers (Medical Institutional Review Board, Howard University; UAB

Institutional Review Board for Human Use, University of Alabama at Brimingham; University of

California Irvine Institutional Review Board, University of California Irvine; Committee for the

Protection of Human Subjects/Institutional Review Board, University of Oregon in collaboration

with the University of Hawaii Biomedical Institutional Review Board, University of

Hawaii/Honolulu; and London Health Sciences Centre Research Institute, London Health Sciences

Centre) gave ethical approvals of the Study protocol that is described in detail elsewhere.[5 15 16]

Participant consent statement

HEIRS Study participants ≥ 25 years of age were recruited from outpatient facilities affiliated with

the Field Centers and gave written informed consent for screening and post-screening evaluation.[5]

[15] [16] The HEIRS Study informed consent forms, not available as public documents, were used

during the participant recruitment phase of the Study (2001-2002). Each of the Field Centers in

North America used an Institutional Review Board-approved consent form tailored to its specific

institution.[5] [15] [16]

Primary care-based screening

The HEIRS Study recruited participants from public and private primary care offices in ambulatory

clinics, a health maintenance organization, and diagnostic blood collection centers affiliated with

five Field Centers.[5] Ninety-eight percent of self-reported non-Hispanic white participants were

recruited at Field Centers in Alabama, California, Ontario, and Oregon/Hawaii.[17] Laboratory

testing at screening included only TS and SF phenotyping and *HFE* p.C282Y and p.H63D allele-

specific genotyping.[5] p.C282Y/p.H63D compound heterozygosity was identified in 908 of 44,082

non-Hispanic white adult screening participants (2.06% [95% confidence interval (CI): 1.93,

2.91]).[17] Medical histories were not compiled and physical examinations were not performed at

primary care-based screening.

Post-screening evaluation attendees

Invitations to attend post-screening evaluations were extended to all 78 participants with *HFE*

p.C282Y/p.H63D compound heterozygosity whose screening TS and SF values were elevated (TS

>50% and SF >300 µg/L for men; TS >45% and SF >200 µg/L for women).[15] [18] Post-screening

evaluation attendees included 77 of the 78 invitees (39 men, 38 women). We excluded two men

and one woman because they had anemia (hemoglobin (Hb) <130 g/L (men) and <120 g/L

(women), pregnancy, or medication use that increased MCV.[19] The cohort for analysis consisted of 74 participants (37 men, 37 women).

Post-screening evaluations

Evaluations included the following: 1) questionnaires completed by participants that addressed medical histories and medications;[18] 2) University of Hawaii Multiethnic Dietary Questionnaires;[18 20] 3) focused physical examinations performed by HEIRS Study physicians;[18] and 4) laboratory testing of blood specimens.[18] The median interval between primary care-based screening and post-screening evaluations was eight months.[18]

Medical history questionnaires

We defined reports of diabetes as affirmative responses to this question: "Have you ever been told you have diabetes?" We defined reports of cirrhosis as affirmative responses to this question: "Ever told that you have/had cirrhosis?"

Dietary questionnaires

Analyses of Multiethnic Dietary Questionnaires at the University of Hawaii provided estimates of the average daily intakes of dietary iron, supplemental iron, and alcohol for the previous year.[18 20] The dietary iron attributed to intakes of meat, fish, and poultry was classified as heme iron and other dietary iron as non-heme iron. Iron intakes were expressed as mg/d. Alcohol intakes were expressed as g/d. We defined heavy alcohol intake as the average intake of more than 14 standard drinks per week (> 28 g/d) for men and more than 7 standard drinks per week (> 14 g/d) for women.[21]

Physical examinations

136 We used Quetelet's formula (kg/m^2) to measure body mass index (BMI).[22] Physicians recorded

137 the presence or absence of swelling or tenderness of the 2nd/3rd metacarpophalangeal (MCP)

138 joints.[18]

Laboratory testing

Blood samples for post-screening testing were obtained after an overnight fast. All participants

were tested for *HFE* genotype confirmation, complete blood count, TS, and SF.[5] Serum alanine

aminotransferase (ALT) and aspartate aminotransferase (AST) levels were available in 46

participants (62.2%). All testing was performed at the HEIRS Study Central Laboratory (Fairview-

University Medical Center Clinical Laboratory, University of Minnesota, Fairview, MN, USA).[15]

[18] Respective mean TS and mean SF values in men and women in screening and post-screening

evaluations did not differ significantly (Table 1).

Table 1. Iron phenotypes in 74 *HFE* p.C282Y/p.H63D compound heterozygotes[a]

Men (n = 37)	Screening	Post-screening evaluation	Value of p
Mean transferrin saturation, % ± 1 SD	65 ± 13	58 ± 17	0.0692
Mean serum ferritin, µg/L ± 1 SD	529 ± 169	531 ± 170	0.9684
Women (n = 37)			
Mean transferrin saturation, % ± 1 SD	59 ± 14	53 ± 12	0.0594
Mean serum ferritin, µg/L ± 1 SD	376 ± 195	366 ± 201	0.8316

150 [a] SD, standard deviation

Markers of advanced hepatic fibrosis or cirrhosis

We calculated fibrosis-4 (FIB-4) indices[23] and AST-to-platelet ratio indices (APRI)[24] as markers

of advanced hepatic fibrosis or cirrhosis risk in the 46 participants (62.2%; 25 men, 21 women)

for whom the requisite data were available. We classified risks with FIB-4 as: low (FIB-4 < 1.3);

intermediate (1.3 ≤ FIB-4 ≤ 2.67); and high (FIB-4 > 2.67).[23] We classified risks with APRI as:

low (APRI < 0.05); intermediate (0.5 < APRI < 1.5); and high (APRI > 1.5).[24] We also compiled

participant reports of cirrhosis diagnoses.

Statistics

The dataset for analyses consisted of complete observations on 74 participants (37 men, 37

women) except FIB-4 and APRI indices (25 men, 21 women). Kolmogorov-Smirnov testing

demonstrated that age, BMI, daily intake of heme iron, TS, SF, and MCV data did not differ

significantly from those that are normally distributed. We displayed these data as means ± 1

standard deviation (SD) and compared means using the Student's t test for unpaired samples (two-

tailed). We displayed other continuous data as medians (ranges) and compared medians using the

Mann-Whitney U test (two-tailed). We compared binary data using Fisher's exact test (two-tailed).

We computed associations of MCV with available continuous variables using Pearson's correlation

(two-tailed) or Spearman's rank correlation (two-tailed) for paired data, as appropriate.

We evaluated these 11 independent variables for suitability in a linear regression on MCV: age,

BMI, sex, diabetes, intakes of heme, non-heme, and supplemental iron and alcohol, swollen or

tender 2nd/3rd MCP joints, TS, and SF. We deleted sex because it was significantly associated with

SF in a Bonferroni-corrected correlation matrix. A preliminary regression on MCV using the

remaining variables revealed low standardized beta coefficients (beta) and high values of p for

BMI, diabetes, non-heme iron intake, swollen or tender 2nd/3rd MCP joints, TS, and SF. Thus, we

excluded these independent variables. We report the contributions of significant remaining

independent variables to the final regression as beta and the proportion of variance in MCV

explained by the independent variable(s) as R^2.

We used Excel® 2022 (Microsoft Corp., Redmond, WA, USA) and GraphPad Prism 8® (2018;

GraphPad Software, San Diego, CA, USA). We defined $p < 0.05$ to be significant.

Results

Characteristics of 74 *HFE* p.C282Y/p.H63D compound heterozygotes

There were 37 men and 37 women of mean age of 59 ± 12 y. Mean MCV was 95.7 ± 4.0 fL. Mean

SF and Hb were higher in men (Table 2). Nine participants (12.2%; 4 men, 5 women) had MCV ≥

100.0 fL.

Table 2. *HFE* p.C282Y/p.H63D compound heterozygotes in post-screening evaluations[a]

Variable	Men (n = 37)	Women (n = 37)	Value of p
Mean age, y (SD)	57 ± 13	62 ± 12	0.0606
Mean body mass index, kg/m^2 (SD)	28.7 ± 5.0	28.0 ± 5.2	0.5405
Diabetes reports, % (n)	24.3 (6)	5.4 (2)	0.2611
Mean heme iron intake, mg/d (SD)	2.4 ± 1.4	1.9 ± 1.0	0.0549
Median non-heme iron intake, mg/d (range)	12.3 (4.2, 34.9)	12.2 (4.3, 43.7)	0.4822
Median supplemental iron intake, mg/d (range)	3.9 (0, 40.5)	3.9 (0, 40.5)	0.6892
Median alcohol intake, g/d (range)	5.7 (0, 60.9)	5.7 (0, 55.8)	0.7949
Swollen or tender 2nd/3rd MCP joints, % (n)	5.4 (2)	5.4 (2)	~1.0000
Mean transferrin saturation, % (SD)	58 ± 17	53 ± 12	0.1197
Mean serum ferritin, μg/L (SD)	531 ± 170	366 ± 201	0.0003
Mean hemoglobin, g/L	155 ±8	139 ± 9	< 0.0001
Mean corpuscular volume, fL (SD)	95.5 ± 4.0	96.0 ± 4.1 fL	0.6087

[a] MCP, metacarpophalangeal; SD, standard deviation

Markers of advanced hepatic fibrosis

High-risk FIB-4 indices were observed in five of 46 participants (10.9%), none of whom had a

high-risk APRI (Table 2). There was no significant difference in mean MCV by low, intermediate,

or high risk FIB-4 or APRI classification (Table 2). One woman reported that she was diagnosed

with cirrhosis, although both her FIB-4 and APRI risks were classified as intermediate.

Table 2. Hepatic fibrosis risk in 46 *HFE* p.C282Y/p.H63D compound heterozygotes[a]

	Low risk, % (n)	Intermediate risk, % (n)	High risk, % (n)	Value of p
FIB-4[b]	56.5 (26)	32.6 (15)	10.9 (5)	-
Mean MCV, fL (SD)	95.7 ± 3.5	96.3 ± 5.6	97.0 ± 5.1	0.8204[d]
APRI[c]	78.3 (36)	21.7 (10)	0 (0)	-
Mean MCV, fL (SD)	96.4 ± 4.0	94.8 ± 5.5	-	0.3140[e]

[a] APRI, AST-to-platelet ratio index; FIB-4, fibrosis-4 index; MCV, mean corpuscular volume; SD,

standard deviation

[b] low risk (FIB-4 < 1.3); intermediate risk (1.3 ≤ FIB-4 ≤ 2.67); and high risk (FIB-4 > 2.67).

[c] low risk (APRI < 0.05); intermediate risk (0.5 < APRI < 1.5); and high risk (APRI > 1.5).

[d] One-way ANOVA p test.

[e] Unpaired Student t test (two-tailed).

MCV correlations with continuous variables

There were significant positive correlations of MCV with age (Fig. 1, Table 3), daily heme iron

intake (Table 3), and daily alcohol intake (Fig. 2, Table 3), and a significant negative correlation

of MCV with BMI (Table 3).

Table 3. Correlations of mean corpuscular volume in 74 *HFE* p.C282Y/p.H63D compound

heterozygotes

Variable	Pearson's coefficient r	Spearman's coefficient *r*	Value of p[a]
Age, y	0.2983	-	0.0098[a]
Body mass index, kg/m^2	−0.2299	-	0.0488
Heme iron intake, mg/d	−0.2478	-	0.0333
Non-heme iron intake, mg/d	-	−0.0604	0.6092
Supplemental iron intake, mg/d	-	0.0742	0.5300
Alcohol intake, g/d	-	0.2860	0.0135[b]
Transferrin saturation, %	0.0667	-	0.5723
Serum ferritin, µg/L	−0.0403	-	0.7296

213 [a] See Figure 1.

214 [b] See Figure 2.

Figure 1. Pearson's correlation of mean corpuscular volume vs. age in 74 *HFE* p.C282Y/p.H63D compound heterozygotes with high iron phenotypes ($r_{74} = 0.2983$; $p = 0.0098$).

Figure 2. Spearman's rank correlation of mean corpuscular volume vs. daily alcohol intake in 74 *HFE* p.C282Y/p.H63D compound heterozygotes with high iron phenotypes ($r_{74} = 0.2860$; $p = 0.0135$).

Mean MCV and binary variables

Mean MCV did not differ significantly between men and women or between participants with and

without diabetes reports or swollen or tender 2nd/3rd MCP joints (Table 4).

Table 4. Mean corpuscular volume in 74 *HFE* p.C282Y/p.H63D compound heterozygotes[a]

Variable	Mean MCV, fL ± SD with variable (n)	Mean MCV, fL ± SD without variable (n)	Value of p
Male sex	95.5 ± 4.0 (37)	96.0 ± 4.1 (37)	0.6087
Diabetes reports	94.6 ± 3.3 (8)	95.8 ± 4.2 (66)	0.4045
Swollen or tender 2nd/3rd MCP joints	97.0 ± 5.5 (4)	95.6 ± 4.0 (70)	0.6768

[a] MCP, metacarpophalangeal; MCV, mean corpuscular volume; SD, standard deviation

MCV and heavy alcohol intakes

The mean MCV of the 19 participants (10 men, 9 women) with heavy alcohol intakes was greater

than the mean MCV of the other 55 participants (97.8 ± 3.8 vs. 95.0 ± 3.9, respectively; p =

0.0074). Four men and two women with heavy alcohol intakes had MCV ≥ 100 fL.

Regression on MCV

Linear regression on MCV using the independent variables age, daily heme iron intake, and daily

alcohol intake revealed positive associations with age (p = 0.0064; beta 0.3055) and daily alcohol

intake (p = 0.0151; beta 0.2707). The R^2 (adjusted R^2) was 0.1622 (0.1386). ANOVA p of this

regression was 0.0019.

Discussion

The novel findings of this study of 74 *HFE* p.C282Y/p.H63D compound heterozygotes with

elevated screening TS and SF are that MCV was significantly associated with both age and daily

alcohol intake after adjustment for other variables. An unexpected finding is that MCV was not

significantly associated with TS, in contrast to observations in p.C282Y homozygotes.[9][25][26][27]

Increasing MCV of the present *HFE* p.C282Y/p.H63D compound heterozygotes was associated

with increasing age. MCV also increased with age in post-screening p.C282Y homozygotes[27] and

English adults in primary care venues.[28] Increasing age[29] and MCV[30] are inversely related to

leukocyte telomere lengths (LTLs). In a Mendelian randomization study, an increase of one

standard deviation in genetically influenced telomere length decreased MCV significantly.[31] In

another study, mean LTL in p.C282Y homozygotes with and without elevated iron phenotypes did

not differ significantly.[32] These observations suggest that genetic determinants of telomere

length,[31] not *HFE* genotypes or iron phenotypes, account in part for the age-related increase in

MCV we observed in the present p.C282Y/p.H63D compound heterozygotes.

There was a moderate negative correlation of MCV with BMI in this study, although MCV was

not significantly associated with BMI after adjustment for other variables. In self-reported healthy

subjects aged > 18 y in the 2011-2016 National Health and Nutrition Examination Survey, there

was a weak negative association of MCV with BMI.[33]

Mean MCV of the present *HFE* p.C282Y/p.H63D compound heterozygotes with and without

diabetes reports did not differ significantly. The mean MCV of Scottish adults with diabetes was

significantly higher than that of control subjects.[34] In contrast, the mean MCV of Indian adults

with type 2 diabetes was significantly lower than that of control subjects.[35]

There was a weak positive correlation of MCV with daily heme iron intake in this study, although

MCV was not significantly associated with daily heme iron intake after adjustment for other

variables. In Dutch blood and plasma donors, MCV was positively associated with heme iron

intakes in men but not in women.[36]

MCVs of the present *HFE* p.C282Y/p.H63D compound heterozygotes were positively associated

with daily alcohol intakes. The mean MCV of Australian men and women with any p.C282Y

genotype also increased with alcohol intake after adjustment for age.[37] In the same study, neither

p.C282Y nor p.H63D alone predisposed to moderate or heavy alcohol intake.[37] In British adults

without anemia, MCV also increased with alcohol intake, but there was no interaction between

alcohol consumption and allelic variants associated with MCV.[38]

The present *HFE* p.C282Y/p.H63D compound heterozygotes were invited to attend post-screening

evaluations because their screening TS and SF values were elevated.[15] Heavy alcohol intake

occurred in 25.7% of the present compound heterozygotes, whereas heavy alcohol intake occurs

in ~6.5% of non-Hispanic white adults in the U.S.[21] Alcohol intake was excessive in 38.9% of

Australian p.C282Y/p.H63D compound heterozygotes with hemochromatosis and SF > 1000

µg/L.[39] Excessive alcohol intake increases TS[40 41] and SF.[42] These observations suggest that 1)

alcohol intake is a major cause of elevated MCV in p.C282Y/p.H63D compound heterozygotes

with both elevated TS and elevated SF and 2) the present post-screening examination invitation

criteria of both elevated TS and elevated SF preferentially although unintentionally selected

p.C282Y/p.H63D compound heterozygotes with heavy daily alcohol intakes.

Swollen or tender 2nd/3rd MCP joints were not associated with MCV and macrocytosis in this

study, in contrast to observations in *HFE* p.C282Y homozygotes.[27] [43] The prevalence of swollen

or tender 2nd/3rd MCP joints in the present p.C282Y/p.H63D compound heterozygotes was lower

than that of post-screening participants with p.C282Y homozygosity (5.4% and 14.4%,

respectively; $p = 0.0246$).[27]

It was unexpected that MCVs in the present *HFE* p.C282Y/p.H63D compound heterozygotes were

not significantly associated with TS, in contrast to the positive associations between MCV and TS

in p.C282Y homozygotes.[9] [26] [27] Mean TS is significantly lower in untreated p.C282Y/p.H63D

compound heterozygotes than untreated p.C282Y homozygotes.[5] This suggests that the mean TS

in p.C282Y/p.H63D compound heterozygotes is insufficient to increase the uptake of transferrin-

bound iron by immature erythroid cells, increase Hb synthesis, and thereby increase MCV.[9]

Limitations of this study include the lack of observations of *HFE* p.C282Y/p.H63D participants

without both elevated TS and SF and of participants aged < 25 y.[5] The HEIRS Study did not

measure serum levels of vitamin B12 or folate, although none of the present subjects had anemia

and deficiencies of these micronutrients were uncommon causes of macrocytosis in another

primary care cohort.[44] More than three-quarters of the variance in MCV values in the present linear

regression is attributable to variables we did not analyze, especially non-*HFE* genetic factors.[11] [31]

[38] Measuring iron stores using quantitative phlebotomy or liver specimens obtained by biopsy and

performing clinical evaluations for cirrhosis were beyond the scope of the cross-sectional HEIRS

Study.

None of 46 participants had combination of high-risk FIB-4 and APRI indices. It is unknown

whether any of the other 28 participants (37.8%) would have had high-risk FIB-4 and APRI indices

or not, although none of them reported a diagnosis of cirrhosis. The prevalence of documented

iron overload-related disease (including cirrhosis) was low in other cohorts of *HFE*

p.C282Y/p.H63D compound heterozygotes.[45][46] These observations suggest the prevalence of

occult advanced hepatic fibrosis or cirrhosis is also low in the present cohort and unlikely to

influence the present results significantly.

Conclusion

We conclude that MCV in *HFE* p.C282Y/p.H63D compound heterozygotes with high iron

phenotypes is positively associated with age and daily alcohol intake, after adjustment for other

variables.

Acknowledgements

and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda,

Maryland); Helen Harrison, RN (The Western-Fanshawe Collaborative BScN Program, Fanshawe

College, London, Ontario, Canada); Christine E. McLaren, PhD (Department of Epidemiology,

University of California, Irvine, California); and Gordon D. McLaren, MD (Division of

Hematology/Oncology, Department of Medicine, University of California, Irvine, and Department

of Veterans Affairs Long Beach Healthcare System, Long Beach, California).

Authors' contributions

Each author contributed substantively to this study. JaCB conceived this study and its

methodology, collected data, evaluated participants in post-screening evaluations, performed

analyses, and drafted the manuscript. JClB conceived study methodology, curated data, performed

analyses, and drafted the manuscript. RTA conceived this study and its methodology, collected

data, performed analyses, curated data, and drafted the manuscript. Each author approved the

manuscript in its final form.

Competing interest statement

350   The authors report no conflict of interest. The authors and their respective institutions have not

351   received any payments or services in the past 36 months from a third party that could be perceived

352   to influence, or give the appearance of potentially influencing, the submitted work.

Funding statement

The National Heart, Lung, and Blood Institute and the National Human Genome Research Institute

had major roles in the HEIRS Study design, data collection, data analyses, and funding, but had

no role in the decision to publish the present work. The authors received additional funding from

Southern Iron Disorders Center for performing data curation and analysis and manuscript

composition pertinent to this submission.

Data Sharing Statement

The National Heart, Lung, and Blood Institute provides controlled access to individual participant

data through the Biologic Specimen and Data Repository Information Coordinating Center

(BioLINCC) (https://biolincc.nhlbi.nih.gov/studies/heirs/). Data access requires registration,

evidence of local institutional review board approval or certification of exemption from

institutional review board review, and completion of a data use agreement. The National Heart,

Lung, and Blood Institute does not permit investigators to submit data directly to journals, related

repositories, or other sources. Parties interested in obtaining the data analyzed in the present study

are referred to BioLINCC.

References

1. Barton JC, Edwards CQ, Acton RT. *HFE* gene: Structure, function, mutations, and

associated iron abnormalities. *Gene;*2015;**574**:179-192. doi: 10.1016/j.gene.2015.10.009

2. Girelli D, Busti F, Brissot P*, et al.* Hemochromatosis classification: update and

recommendations by the BIOIRON Society. *Blood;*2022;**139**:3018-3029. doi:

10.1182/blood.2021011338

3. Ganz T. Hepcidin and iron regulation, 10 years later. *Blood;*2011;**117**:4425-4433. doi:

10.1182/blood-2011-01-258467

4. Merryweather-Clarke AT, Pointon JJ, Shearman JD*, et al.* Global prevalence of putative

haemochromatosis mutations. *J Med Genet;*1997;**34**:275-278. doi: 10.1136/jmg.34.4.275

5. Adams PC, Reboussin DM, Barton JC*, et al.* Hemochromatosis and iron-overload

screening in a racially diverse population. *N Engl J Med;*2005;**352**:1769-1778. doi:

10.1056/NEJMoa041534

6. Means RTJr, Glader B. Anemia: general considerations. In: Means RT Jr, Rodgers GM,

Glader B et al., eds. Wintrobe's Clinical Hematology. Philadelphia: Wolters Kluwer;

2024:600-627.

7. Rossi E, Olynyk JK, Cullen DJ*, et al.* Compound heterozygous hemochromatosis genotype

predicts increased iron and erythrocyte indices in women. *Clin Chem;*2000;**46**:162-166.

8. Rossi E, Bulsara MK, Olynyk JK, *et al.* Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population. *Clin Chem;*2001;**47**:202-208.

9. Barton JC, Bertoli LF, Rothenberg BE. Peripheral blood erythrocyte parameters in hemochromatosis: evidence for increased erythrocyte hemoglobin content. *J Lab Clin Med;*2000;**135**:96-104. doi: 10.1016/s0022-2143(00)70026-6

10. de Valk B, Witlox RS, van der Schouw YT, *et al.* Biochemical expression of heterozygous hereditary hemochromatosis. *Eur J Intern Med;*2000;**11**:317-321. doi: 10.1016/s0953-6205(00)00111-4

11. Ganesh SK, Zakai NA, van Rooij FJ, *et al.* Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. *Nat Genet;*2009;**41**:1191-1198. doi: 10.1038/ng.466

12. Kullo IJ, Ding K, Jouni H, *et al.* A genome-wide association study of red blood cell traits using the electronic medical record. *PLoS One;*2010;**5**:e13011. doi: 10.1371/journal.pone.0013011

13. McLaren CE, Garner CP, Constantine CC, *et al.* Genome-wide association study identifies genetic loci associated with iron deficiency. *PLoS One;*2011;**6**:e17390. doi: 10.1371/journal.pone.0017390

14. Feeney GP, Carter K, Masters GS, *et al.* Changes in erythropoiesis in hereditary hemochromatosis are not mediated by HFE expression in nucleated red cells. *Haematologica;*2005;**90**:180-187.

15. McLaren CE, Barton JC, Adams PC, *et al.* Hemochromatosis and Iron Overload Screening (HEIRS) Study design for an evaluation of 100,000 primary care-based adults. *Am J Med Sci;*2003;**325**:53-62. doi: 10.1097/00000441-200302000-00001

16. Hemochromatosis and Iron Overload Screening Study (HEIRS) January 2000-January 2006. Available at: https://biolincc.nhlbi.nih.gov/studies/heirs/. Accessed 16 October 2025.

17. Barton JC, Acton RT, Dawkins FW, *et al.* Initial screening transferrin saturation values, serum ferritin concentrations, and *HFE* genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. *Genet Test;*2005;**9**:231-241. doi: 10.1089/gte.2005.9.231

18. McLaren GD, McLaren CE, Adams PC, *et al.* Clinical manifestations of hemochromatosis in *HFE* C282Y homozygotes identified by screening. *Can J Gastroenterol;*2008;**22**:923-930. doi: 10.1155/2008/907356

19. Nagao T, Hirokawa M. Diagnosis and treatment of macrocytic anemias in adults. *J Gen Fam Med;*2017;**18**:200-204. doi: 10.1002/jgf2.31

20. Stram DO, Hankin JH, Wilkens LR, *et al.* Calibration of the dietary questionnaire for a multiethnic cohort in Hawaii and Los Angeles. *Am J Epidemiol;*2000;**151**:358-370. doi: 10.1093/oxfordjournals.aje.a010214

21. Boersma, P., Villarroel, M. A., and Vahratian, A. Heavy Drinking Among U.S. Adults, 2018. Available at: https://www.cdc.gov/nchs/data/databriefs/db374-h.pdf. Accessed September 15, 2025.

22. Eknoyan G. Adolphe Quetelet (1796-1874)--the average man and indices of obesity.

*Nephrol Dial Transplant;*2008;**23**:47-51. doi: gfm517 [pii];10.1093/ndt/gfm517 [doi]

23. Shah AG, Lydecker A, Murray K*, et al.* Comparison of noninvasive markers of fibrosis in

patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol;*2009;**7**:1104-

1112. doi: 10.1016/j.cgh.2009.05.033

24. Borroni G, Ceriani R, Cazzaniga M*, et al.* Comparison of simple tests for the non-invasive

diagnosis of clinically silent cirrhosis in chronic hepatitis C. *Aliment Pharmacol*

*Ther;*2006;**24**:797-804. doi: 10.1111/j.1365-2036.2006.03034.x

25. McLaren CE, Barton JC, Gordeuk VR*, et al.* Determinants and characteristics of mean

corpuscular volume and hemoglobin concentration in white *HFE* C282Y homozygotes in

the Hemochromatosis and Iron Overload Screening Study. *Am J Hematol;*2007;**82**:898-

905. doi: 10.1002/ajh.20937

26. Adris N, Hazeldine S, Bentley P*, et al.* Detection of *HFE* haemochromatosis in the clinic

and community using standard erythrocyte tests. *Blood Cells Mol Dis;*2019;**74**:18-24. doi:

10.1016/j.bcmd.2018.10.003

27. Barton JC, Barton JC, Acton RT. Factors related to mean corpuscular volume in *HFE*

p.C282Y homozygotes. *ejHaem;*2024;**6**:e1063. doi: 10.1002/jha2.1063

28. Phillips R, Wood H, Weaving G*, et al.* Changes in full blood count parameters with age

and sex: results of a survey of almost 900 000 patient samples from primary care. *Br J*

*Haematol;*2021;**192**:e102-e105. doi: 10.1111/bjh.17290

29. Frenck RW, Jr., Blackburn EH, Shannon KM. The rate of telomere sequence loss in human
leukocytes varies with age. *Proc Natl Acad Sci U S A;*1998;**95**:5607-5610. doi:
10.1073/pnas.95.10.5607

30. Kozlitina J, Garcia CK. Red blood cell size is inversely associated with leukocyte telomere
length in a large multi-ethnic population. *PLoS One;*2012;**7**:e51046. doi:
10.1371/journal.pone.0051046

31. Adams CD, Boutwell BB. A Mendelian randomization study of telomere length and blood-
cell traits. *Sci Rep;*2020;**10**:12223. doi: 10.1038/s41598-020-68786-6

32. Mainous AG, III, Wright RU, Hulihan MM*, et al.* Telomere length and elevated iron: the
influence of phenotype and *HFE* genotype. *Am J Hematol;*2013;**88**:492-496. doi:
10.1002/ajh.23438

33. Thavaraputta S, Dennis JA, Ball S*, et al.* Relation of hematologic inflammatory markers
and obesity in otherwise healthy participants in the National Health and Nutrition
Examination Survey, 2011-2016. *Proc (Bayl Univ Med Cent);*2020;**34**:17-21. doi:
10.1080/08998280.2020.1799482

34. Davidson RJ, Evan-Wong LA, Stowers JM. The mean red cell volume in diabetes mellitus.
*Diabetologia;*1981;**20**:583-584. doi: 10.1007/BF00252770

35. Basak M, Dey SK, Ghosh S*, et al.* A clinicopathological investigation on morphological
alterations of red blood cells among treated and untreated type II diabetes mellitus patients.
*Indian J Pathol Microbiol;*2025 doi: 10.4103/ijpm.ijpm_99_25

36. Timmer TC, de GR, Rijnhart JJM*, et al.* Dietary intake of heme iron is associated with

ferritin and hemoglobin levels in Dutch blood donors: results from Donor InSight.

*Haematologica;*2020;**105**:2400-2406. doi: 10.3324/haematol.2019.229450

37. Olynyk JK, Knuiman MW, Divitini ML*, et al.* Effects of *HFE* gene mutations and alcohol

on iron status, liver biochemistry and morbidity. *J Gastroenterol Hepatol;*2005;**20**:1435-

1441. doi: 10.1111/j.1440-1746.2005.03967.x

38. Thompson A, King K, Morris AP*, et al.* Assessing the impact of alcohol consumption on

the genetic contribution to mean corpuscular volume. *Hum Mol Genet;*2021;**30**:2040-2051.

doi: 10.1093/hmg/ddab147

39. Walsh A, Dixon JL, Ramm GA*, et al.* The clinical relevance of compound heterozygosity

for the C282Y and H63D substitutions in hemochromatosis. *Clin Gastroenterol*

*Hepatol;*2006;**4**:1403-1410. doi: 10.1016/j.cgh.2006.07.009

40. Whitfield JB, Zhu G, Heath AC*, et al.* Effects of alcohol consumption on indices of iron

stores and of iron stores on alcohol intake markers. *Alcohol Clin Exp Res;*2001;**25**:1037-

1045.

41. Kroll DS, McPherson KL, Manza P*, et al.* Elevated transferrin saturation in individuals

with alcohol use disorder: association with *HFE* polymorphism and alcohol withdrawal

severity. *Addict Biol;*2022;**27**:e13144. doi: 10.1111/adb.13144

42. Milman N, Kirchhoff M. Relationship between serum ferritin, alcohol intake, and social

status in 2235 Danish men and women. *Ann Hematol;*1996;**72**:145-151. doi:

10.1007/s002770050153

43. Rehman A, Carroll GJ, Powell LW*, et al.* Arthropathy in hereditary haemochromatosis

segregates with elevated erythrocyte mean corpuscular volume. *Scand J*

*Rheumatol;*2021;**50**:139-142. doi: 10.1080/03009742.2020.1800081

44. Wymer A, Becker DM. Recognition and evaluation of red blood cell macrocytosis in the

primary care setting. *J Gen Intern Med;*1990;**5**:192-197. doi: 10.1007/BF02600531

45. Gurrin LC, Bertalli NA, Dalton GW*, et al. HFE* C282Y/H63D compound heterozygotes

are at low risk of hemochromatosis-related morbidity. *Hepatology;*2009;**50**:94-101. doi:

10.1002/hep.22972

46. Hasan SMM, Farrell J, Borgaonkar M. C282Y/H63D compound heterozygosity is a low

penetrance genotype for iron overload-related disease. *J Can Assoc*

*Gastroenterol;*2022;**5**:240-247. doi: 10.1093/jcag/gwac025

504